Aminoguanidine inhibits ventricular fibrosis and remodeling process in isoproterenol-induced hypertrophied rat hearts by suppressing ROS and MMPs

Life Sciences

Volumn 118, Issue 1, 2014, Pages 15-26

  Parthasarathy, Arumugam ^a   Gopi, Venkatachalam ^a   Devi Km, Shyamala ^a   Balaji, Nagarajan ^a   Vellaichamy, Elangovan ^a  

^a UNIVERSITY OF MADRAS   (India)

Author keywords

Aminoguanidine; Cardiac fibrosis; Cardiac hypertrophy; Cardiac remodeling; Extracellular matrix; Isoproterenol; Matrix metalloproteinases

Indexed keywords

AMINOGUANIDINE; CATALASE; COLLAGEN; GELATINASE; GELATINASE A; GELATINASE B; GLUTATHIONE; GLUTATHIONE PEROXIDASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ANTIOXIDANT; GUANIDINE DERIVATIVE; ISOPRENALINE; MATRIX METALLOPROTEINASE INHIBITOR; RELA PROTEIN, RAT; TISSUE INHIBITOR OF METALLOPROTEINASE-1 PROTEIN, RAT; TRANSCRIPTION FACTOR RELA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HEART MUSCLE FIBROSIS; HEART WEIGHT; HISTOPATHOLOGY; ISOPROTERENOL-INDUCED CARDIAC HYPERTROPHY; LIPID PEROXIDATION; MALE; NONHUMAN; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN SYNTHESIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; ANIMAL; CARDIOMEGALY; CHEMICALLY INDUCED; DRUG EFFECTS; FIBROSIS; GENETICS; HEART VENTRICLE; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; WISTAR RAT;

RATTUS;

ANIMALS; ANTIOXIDANTS; CARDIOMEGALY; FIBROSIS; GUANIDINES; HEART VENTRICLES; ISOPROTERENOL; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; RATS, WISTAR; REACTIVE OXYGEN SPECIES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSCRIPTION FACTOR RELA; VENTRICULAR REMODELING;

EID: 84909966596     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2014.09.030     Document Type: Article

References (64)

1. I.J. Benjamin, J.E. Jalil, L.B. Tan, K. Cho, K.T. Weber, and W.A. Clark Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis Circ. Res. 65 1989 657 670
2. I. Bergman, and R. Loxley Two improved and simplified methods for the spectrophotometric determination of hydroxyproline Anal. Chem. 35 1963 1961 1965
3. B.C. Berk, K. Fujiwara, and S. Lehoux ECM remodeling in hypertensive heart disease J. Clin. Invest. 117 2007 568 575
4. K. Brew, and H. Nagase The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity Biochim. Biophys. Acta 2010 1803 55 71
5. M.M. Castro, and J.E. Tanus-Santos Inhibition of matrix metalloproteinases (MMPs) as a potential strategy to ameliorate hypertension-induced cardiovascular alterations Curr. Drug Targets 14 2013 335 343
6. S. Chakraborti, M. Mandal, S. Das, A. Mandal, and T. Chakraborti Regulation of matrix metalloproteinases: an overview Mol. Cell. Biochem. 253 2003 269285
7. K.C. Chang, K.L. Hsu, C.D. Tseng, Y.D. Lin, Y.L. Cho, and Y.Z. Tseng Aminoguanidine prevents arterial stiffening and cardiac hypertrophy in streptozotocin-induced diabetes in rats Br. J. Pharmacol. 147 2006 944 950
8. C.H. Conrad, W.W. Brooks, J.A. Hayes, S. Sen, K.G. Robinson, and O.H. Bing Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat Circulation 91 1995 161 170
9. E.E. Creemers, J.P. Cleutjens, J.F. Smits, and M.J. Daemen Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ. Res. 89 2001 201 210
10. A. Ducharme, S. Frantz, M. Aikawa, E. Rabkin, M. Lindsey, and L.E. Rohde Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction J. Clin. Invest. 106 2000 55 62
11. G.L. Ellman Tissue sulfhydryl groups Arch. Biochem. Biophys. 82 1959 70 77
12. I. Giardino, A.K. Fard, D.L. Hatchell, and M. Brownlee Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis Diabetes 47 1998 1114 1120
13. M.M. Givertz, D.B. Sawyer, and W.S. Colucci Antioxidants and myocardial contractility: illuminating the "Dark Side" of beta-adrenergic receptor activation? Circulation 103 2001 782 783
14. A. Goldin, J.A. Beckman, A.M. Schmidt, and M.A. Creager Advanced glycation end products: sparking the development of diabetic vascular injury Circulation 114 2006 597 605
15. T. Hamid, S.Z. Guo, J.R. Kingery, X. Xiang, B. Dawn, and S.D. Prabhu Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure Cardiovasc. Res. 89 2011 129 138
16. S. Hayashidani, H. Tsutsui, M. Ikeuchi, T. Shiomi, H. Matsusaka, and T. Kubota Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction Am. J. Physiol. Heart Circ. Physiol. 285 2003 229 235
17. L.C. Heather, A.F. Catchpole, D.J. Stuckey, M.A. Cole, C.A. Carr, and K. Clarke Isoproterenol induces in vivo functional and metabolic abnormalities: similar to those found in the infarcted rat heart J. Physiol. Pharmacol. 60 2009 31 39
18. Y. Hori, S. Kunihiro, S. Sato, K. Yoshioka, Y. Hara, and K. Kanai Doxycycline attenuates isoproterenol-induced myocardial fibrosis and matrix metalloproteinase activity in rats Biol. Pharm. Bull. 32 2009 1678 1682
19. M.A. Horn, H.K. Graham, M.A. Richards, J.D. Clarke, D.J. Greensmith, and S.J. Briston Age-related divergent remodeling of the cardiac extracellular matrix in heart failure: collagen accumulation in the young and loss in the aged J. Mol. Cell. Cardiol. 53 2012 82 90
20. G. Jones, P. Willett, R.C. Glen, A.R. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748
21. P. Kakkar, B. Dos, and P.N. Viswanathan A modified spectrophotometric assay of superoxide dismutase Indian J. Biochem. Biophys. 21 1984 130 132
22. V. Kandalam, R. Basu, L. Moore, D. Fan, X. Wang, and D.M. Jaworski Lack of tissue inhibitor of metalloproteinases 2 leads to exacerbated left ventricular dysfunction and adverse extracellular matrix remodeling in response to biomechanical stress Circulation 124 2011 2094 2105
23. S.G. Kang, G. Zhou, P. Yang, Y. Liu, B. Sun, T. Huynh, H. Meng, L. Zhao, G. Xing, C. Chen, Y. Zhao, and R. Zhou Molecular mechanism of pancreatic tumor metastasis inhibition by Gd@C82(OH)22 and its implication for de novo design of nanomedicine Proc. Natl. Acad. Sci. 109 2012 15431 15436
24. S. Kinugawa, H. Tsutsui, S. Hayashidani, T. Ide, N. Suematsu, and S. Satoh Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress Circ. Res. 87 2000 392 398
25. S.K. Koshy, H.K. Reddy, and H.H. Shukla Collagen cross-linking: new dimension to cardiac remodeling Cardiovasc. Res. 57 2003 594 598
26. V. Le Guilloux, P. Schmidtke, and P. Tuffery Fpocket: an open source platform for ligand pocket detection BMC Bioinforma. 10 2009 168
27. C.P. LeBel, I.N. Odunze, J.D. Adams Jr., and S.C. Bondy Perturbations in cerebral oxygen radical formation and membrane order following vitamin E deficiency Biochem. Biophys. Res. Commun. 163 1989 860 866
28. H. Li, H. Simon, T.M. Bocan, and J.T. Peterson MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition Cardiovasc. Res. 46 2000 298 306
29. Y. Li, T. Ha, X. Gao, J. Kelley, D.L. Williams, I.W. Browder, R.L. Kao, and C. Li NF-kappaB activation is required for the development of cardiac hypertrophy in vivo Am. J. Physiol. Heart Circ. Physiol. 287 2004 H1712 H1720
30. Y.Y. Li, Y.Q. Feng, T. Kadokami, C.F. McTiernan, R. Draviam, and S.C. Watkins Myocardial extracellular matrix remodeling in transgenic mice over expressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy Proc. Natl. Acad. Sci. 97 2000 12746 12751
31. Y.Y. Li, C.F. McTiernan, and A.M. Feldman Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling Cardiovasc. Res. 46 2000 214 224
32. H.G. Lobo Filho, N.L. Ferreira, R.B. Sousa, E.R. Carvalho, P.L. Lobo, and J.G. Lobo Filho Experimental model of myocardial infarction induced by isoproterenol in rats Rev. Bras. Cir. Cardiovasc. 26 2011 469 476
33. F.X. Maquart, L. Pickart, M. Laurent, P. Gillery, J.C. Monboisse, and J.P. Borel Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-l-histidyl-l-721 lysine-Cu2 + FEBS Lett. 238 1988 343 346
34. C. Marchesi, F. Dentali, E. Nicolini, A.M. Maresca, M.H. Tayebjee, and M. Franz Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis J. Hypertens. 30 2012 3 16
35. S.K. Maulik, P. Prabhakar, A.K. Dinda, and S. Seth Genistein prevents isoproterenol-induced cardiac hypertrophy in rats Can. J. Physiol. Pharmacol. 90 2012 1117 1125
36. B. Menon, M. Singh, and K. Singh Matrix metalloproteinases mediate beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes Am. J. Physiol. Cell Physiol. 289 2005 168 176
37. K.S. Moshal, W.E. Rodriguez, U. Sen, and S.C. Tyagi Targeted deletion of MMP-9 attenuates myocardial contractile dysfunction in heart failure Physiol. Res. 57 2008 379 384
38. D. Mukherjee, and S. Sen Alteration of collagen phenotypes in ischemic cardiomyopathy J. Clin. Invest. 88 1991 1141 1146
39. H. Nagase, R. Visse, and G. Murphy Structure and function of matrix metalloproteinases and TIMPs Cardiovasc. Res. 69 2006 562 573
40. K.K. Nelson, and J.A. Melendez Mitochondrial redox control of matrix metalloproteinases Free Radic. Biol. Med. 37 2004 768 784
41. Z. Nichtova, M. Novotova, E. Kralova, and T. Stankovicova Morphological and functional characteristics of models of experimental myocardial injury induced by isoproterenol Gen. Physiol. Biophys. 31 2012 141 151
42. E.L. Nirdlinger, and P.O. Bramante Subcellular myocardial ionic shifts and mitochondrial alterations in the course of isoproterenol-induced cardiopathy of the rat J. Mol. Cell. Cardiol. 6 1974 49 60
43. T.J. O'Farrell, and T. Pourmotabbed Identification of structural elements important for matrix metalloproteinase type V collagenolytic activity as revealed by chimeric enzymes. Role of fibronectin-like domain and active site of gelatinase B J. Biol. Chem. 275 2000 27964 27972
44. H. Ohkawa, N. Ohishi, and K. Yagi Assay of lipid peroxidation on animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358
45. S. Poitevin, R. Garnotel, F. Antonicelli, P. Gillery, and P. Nguyen Type I collagen induces tissue factor expression and matrix metalloproteinase 9 production in human primary monocytes through a redox-sensitive pathway J. Thromb. 6 2008 15861594
46. S. Rajagopalan, X.P. Meng, S. Ramasamy, D.G. Harrison, and Z.S. Galis Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability J. Clin. Invest. 9811 1996 2572 2579
47. F. Remiao, H. Carmo, F.D. Carvalho, and M.L. Bastos Inhibition of glutathione reductase by isoproterenol oxidation products J. Enzym. Inhib. 15 2000 47 61
48. A.M. Romanic, S.M. Harrison, W. Bao, C.L. Burns-Kurtis, S. Pickering, and J. Gu Myocardial protection from ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9 Cardiovasc. Res. 54 2002 549 558
49. J.T. Rotruk, A.L. Pope, H.E. Ganther, A.B. Swanson, D.G. Hafeman, and W.G. Hekstra Selenium, biochemical role as a component of glutathione peroxidase purification and assay Science 179 1973 588 590
50. B. Schwartzkopff, M. Fassbach, B. Pelzer, M. Brehm, and B.E. Strauer Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy Eur. J. Heart Fail. 4 2002 (439-4)
51. A. Shirakabe, K. Asai, N. Hata, S. Yokoyama, T. Shinada, and N. Kobayashi Immediate administration of atorvastatin decreased the serum MMP-2 level and improved the prognosis for acute heart failure J. Cardiol. 59 2012 374 382
52. A.K. Sinha Colorimetric assay of catalase Anal. Biochem. 47 1972 389 394
53. S. Srivastava, B. Chandrasekar, Y. Gu, J. Luo, T. Hamid, and B.G. Hill Downregulation of CuZn-superoxide dismutase contributes to beta-adrenergic receptor-mediated oxidative stress in the heart Cardiovasc. Res. 74 2007 445 455
54. C. Szabó, G. Ferrer-Sueta, B. Zingarelli, G.J. Southan, A.L. Salzman, and R. Radi Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage J. Biol. Chem. 272 1997 9030 9036
55. T. Tuccinardi, E. Nuti, G. Ortore, A. Rossello, S.I. Avramova, and A. Martinelli Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors Bioorg. Med. Chem. 16 2008 7749 7758
56. D. Vanhoutte, M. Schellings, Y. Pinto, and S. Heymans Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window Cardiovasc. Res. 69 2006 604 613
57. E. Vellaichamy, M.L. Khurana, J. Fink, and K.N. Pandey Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A J. Biol. Chem. 280 2005 19230 19242
58. R. Visse, and H. Nagase Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry Circ. Res. 92 2003 827 839
59. M.C. Vozenin-Brotons, V. Sivan, and N. Gault Antifibrotic action of Cu/Zn SOD is mediated by TGF-β1 repression and phenotypic reversion of myofibroblasts Free Radic. Biol. Med. 30 2001 30 42
60. I. Wandzik Interactions between glycosyltransferases and 2-deoxy glycosyl derivatives of uridine simulated by molecular docking Acta Pol. Pharm. 65 2008 735 741
61. Z. Wang, R. Juttermann, and P.D. Soloway TIMP-2 is required for efficient activation of proMMP-2 in vivo J. Biol. Chem. 275 2000 26411 26415
62. S. Xu, H. Zhi, X. Hou, R.A. Cohen, and B. Jiang IκBβ attenuates angiotensin II-induced cardiovascular inflammation and fibrosis in mice Hypertension 58 2011 310 316
63. K. Yamamoto, T. Masuyama, Y. Sakata, N. Nishikawa, T. Mano, and J. Yoshida Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart Cardiovasc. Res. 55 2002 76 82
64. G.X. Zhang, S. Kimura, A. Nishiyama, T. Shokoji, M. Rahman, and L. Yao Cardiac oxidative stress in acute and chronic isoproterenol-infused rats Cardiovasc. Res. 65 2005 230 238